![](https://endpts.com/wp-content/uploads/2021/04/Vas-Narasimhan-getty-scaled.jpg)
Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
Novartis to buy MorphoSys for $2.9B after 20 years of creating antibodies with the German biotech
Novartis inked a deal to buy MorphoSys for $2.9 billion, in a move that gives the Swiss Big Pharma a cancer drug on the verge …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.